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BRIEF COMMUNICATION OPEN
Breast cancer gene expression datasets do not reflect the disease
at the population level
Yanping Xie1,2, Brittny C. Davis Lynn3, Nicholas Moir1, David A. Cameron4, Jonine D. Figueroa 1,2✉ and Andrew H. Sims 1✉
Publicly available tumor gene expression datasets are widely reanalyzed, but it is unclear how representative they are of clinical
populations. Estimations of molecular subtype classification and prognostic gene signatures were calculated for 16,130 patients
from 70 breast cancer datasets. Collated patient demographics and clinical characteristics were sparse for many studies.
Considerable variations were observed in dataset size, patient/tumor characteristics, and molecular composition. Results were
compared with Surveillance, Epidemiology, and End Results Program (SEER) figures. The proportion of basal subtype tumors ranged
from 4 to 59%. Date of diagnosis ranged from 1977 to 2013, originating from 20 countries across five continents although European
ancestry dominated. Publicly available breast cancer gene expression datasets are a great resource, but caution is required as they
tend to be enriched for high grade, ER-negative tumors from European-ancestry patients. These results emphasize the need to
derive more representative and annotated molecular datasets from diverse populations.
npj Breast Cancer            (2020) 6:39 ; https://doi.org/10.1038/s41523-020-00180-x
INTRODUCTION
An ever-increasing number of cancer transcriptomics datasets are
now publicly available enabling researchers to perform highly
informative retrospective gene expression analysis. The majority of
these transcriptome microarray and RNAseq datasets are still
relatively small, limited to 20–300 patients, except for large
consortia studies such as TCGA1 and METABRIC2. Even relatively
small studies can be repurposed to provide valuable insights,
particularly if they have detailed information on the tumor and
patient characteristics. Gene expression data from functional
studies in cancer cell lines or in vivo experiments can be
compared with clinical datasets to evaluate the reliability of
model systems to recapitulate the disease. These clinical datasets
can also be used to assess associations between putative
oncogenes or tumor suppressors and different signaling pathways
or clinical characteristics to examine whether certain subgroups of
tumors have elevated or reduced expression of particular genes.
To better understand the variability and the extent to which
these datasets represent breast cancers at the population level, a
comprehensive analysis of molecular subtypes and prognostic
signatures across all publicly available datasets was performed. A
total of 70 breast cancer gene expression datasets representing
16,130 patients were examined. Limited patient and tumor
information was provided for many of studies and wide variations
in molecular composition were uncovered between the cohorts.
Publicly available datasets were found to be biased towards high
grade, ER-negative tumors from European-ancestry patients
compared with the wider population.
RESULTS
Limited annotation of published gene expression datasets
Availability of clinical annotation associated with each dataset was
limited and highly variable, from reasonably complete information
on country of origin (79%) and decade of diagnosis (68%), to more
sparse details on characteristics such as age at diagnosis (30%),
grade (49%), tumor size (37%) to very scant information on
characteristics like BMI (5%). Molecular subtype assignments were
similar using different classifiers. The PAM50 method was most
concordant across platforms, assessed by 573 replicate tumors
processed by RNAseq and Agilent microarray data from the TCGA
study (Supplementary Fig. 1). The PAM50 and Mammaprint risk of
relapse estimated scores were also highly consistent, although
Mammaprint correlations were a little lower (R2= 0.8) than for
PAM50 scores (R2= 0.9).
Wide variation in molecular composition of studies
The relative proportions of molecular subtypes varied widely
between datasets, with basal tumors ranging from 4 to 59% (Fig.
1). Overall the proportion of basal subtype or ER-negative (35%)
tumors was considerably higher than the 10% HR-/HER2-observed
across broader, unselected populations from the SEER database
2007–20133. It is noteworthy that one dataset (GSE10780) was
dominated by ‘normal-like’ tumors, which were absent from
several others (e.g., GSE28796, GSE6861, GSE22513, and
GSE19615). There appear two possible reasons for these observa-
tions, both a genuine preeminence and absence of minimally
aberrant tumors, or simply that breast tumors in these datasets
had particularly low/high tumor content, given that doubts remain
over the existence of normal-like subtypes4. The proportion of
basal-like tumors significantly decreases with age (Fig. 2a) as has
been shown before in the large American Cancer Society study5.
Some population level epidemiological associations are evident,
but others appear distorted
PAM50 risk of relapse scores for those patients who were younger
than 50 years old and overweight or obese patients were
significantly higher than those of normal weight patients (Fig.
2b), consistent with expectations of the association between BMI
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and poor outcomes6. Not all trends were as expected, the
estimated PAM50 prognostic scores of Asian patients over 50
years old were significantly higher than for Whites (p < 0.01) and
Blacks (p < 0.05), suggesting older Asians had worse predicted
prognosis (Fig. 2c). However, these comparisons are limited and
likely invalid, confounded by much smaller sample sizes biased
towards a greater proportion of high grade tumors among Asian
patients. This serves as a cautionary tale of carefully examining
Fig. 1 Molecular subtypes of breast cancer are highly variable across publicly available datasets. Distributions of PAM50 intrinsic subtypes
assigned by the geneFu package across 70 datasets. The median proportion of luminal A tumors was 25% and luminal B was 31%. Some
datasets were dominated by specific subtypes and some were completely lacking in normal-like breast tumors.
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whether it is reasonable to compare molecular subtypes or
signatures by individual clinical characteristics. The available
molecular datasets reflect patients diagnosed from 1977 to 2013
(median 1994) across a range of care settings, many often in
specialist referral cancer centers, which may be more likely to treat
more aggressive and later stage cancers. Some have many years
of follow-up providing valuable opportunities for survival analysis;
however, it is important to acknowledge that treatment
approaches have changed substantially over the years meaning
that therapy regimes, and thus outcomes, may be very different
for more recently diagnosed patients.
Recent population-based cancer registry studies7–9 have shown
an increase in the incidence rates of ER+ tumors, this pattern was
also apparent in the publicly available datasets (Fig. 2d). However,
the proportion of ER+ tumors is consistently lower in public gene
expression datasets for each decade compared to data from
Surveillance, Epidemiology, and End Results (SEER) Program
(Fig. 2d). Similarly, the proportion of grade 1 tumors is lower in
publicly available gene expression datasets than reported by
SEER (Fig. 2e). Very limited numbers of tumors with published
gene expression data and grade information are currently
available from the 2010s for contemporary comparisons with
the latest population data.
DISCUSSION
This study highlights the challenges of incomplete clinical and
epidemiological information in many studies, the issue of high
variation between datasets and likelihood of confounding due to
limited annotation and bias in the patient population from whom
the samples analyzed were taken. Some datasets more closely
represent the wider or specific populations than others, but
overall, they tend to be enriched for high grade, ER-negative
tumors which may limit the applicability of any conclusions
derived from these resources to the source populations that the
breast cancers originate. The underlying sources of this bias
observed in the public datasets are likely numerous and varied,
primarily influenced by methodological requirements in earlier
years for high tumor content and volumes for genetic profiling
studies and sample availability rather than study design—causing
a higher proportion of high grade ER-negative tumors than
normally would be observed10. We recently highlighted that
technological advances now enable reliable gene expression
profiling of formalin fixed paraffin-embedded samples due to less
stringent RNA extraction requirements11, but most of the datasets
included in this study utilized fresh frozen research samples
collected in addition to routine clinical samples.
The breast cancer research community is fortunate to have
much larger in silico resources in the public domain for reanalysis
Fig. 2 Publicly available breast cancer gene expression datasets recapitulate some epidemiological trends, but have reduced
proportions of ER+ and grade 1 tumors compared with Western populations. The distribution of molecular subtypes by age (a) and the
association between BMI and molecular predictions of poor outcomes (b) are as would be expected. However, Asians older than 50 appear to
have worse predicted prognosis than other races (c), but this is likely confounded by other factors. The boxes represent upper and lower
quartile ranges, horizontal line the median and whiskers indicate 1.5× the interquartile range. Incidence rates for ER-positive tumors
progressively increase overtime, but the proportion remains significantly lower than that reported by SEER (d), vertical bars represent 95%
confidence intervals. Grade 3 tumors were most abundant in publicly available datasets for the 1990s, which does not reflect SEER figures,
which show increasing proportions of grade 1 tumors over the last three decades (e).
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compared to other malignancies. It is hoped that molecular
datasets generated in the future will be more complete for
demographic and clinical information. Most of these datasets are
comprised of women of European descent, but it will also be
necessary to ensure that under-represented groups such as
women of African and Asian descent are appropriately repre-
sented if we are to consider molecular epidemiology of breast
cancer at a global level to ensure precision medicine is accessible
to all. Although it is nearly 20 years since the minimum
information about a microarray experiment MIAME guidelines
were introduced12 and reanalysis of publicly available data has
moved on a long way since then, the guidelines on what
information should be provided with datasets has not really
changed. It does not seem unreasonable that along with
mandating data availability, journals should begin insisting that
minimum patient and tumor clinicopathologic information is
provided (such as sex, age, and race or hospital, along with
histologic grade, nodal status, ER, and HER2 status) for all samples
for studies to be published. Whether and how researchers and
patients could be incentivized to generate more representative
datasets is perhaps more contentious, although it has been shown
that minorities are often under-represented in clinical trials and
steps can be taken to address this13. We recognize that there are
social and historical factors that may affect participation of
minority communities in such efforts, but it is incumbent upon the
scientific community to make appropriate efforts to recruit these
populations.
Tumor gene expression datasets for all cancer types will
continue to proliferate in the public domain, providing a valuable
resource to generate and test hypotheses for individual genes or
signatures. However, researchers should be well aware of wide
variations in terms of size, patient characteristics, and molecular
composition of datasets and that they do not necessarily reflect
the source population diagnosed cancers.
METHODS
Dataset selection and processing
A total of 70 datasets, representing 16,130 breast carcinomas (Summarized
in Supplementary Data Set 1) were identified in the public domain when
restricting the search to those studies representing a minimum of 50
breast cancer patients with primary invasive breast tumors14. Datasets
were generated on 15 different gene expression platforms, but Affymetrix
GeneChips dominated (88%). The datasets were downloaded from
ArrayExpress or NCBI Gene Expression Omnibus. Where available, raw.
CEL files were processed using Custom CDF15 to Entrez gene IDs and fRMA
normalized16. Preprocessed data for other platforms was utilized with
multiple probes for the same gene averaged. Estimations of molecular
subtype classifications and prognostic gene signatures were calculated
using geneFu17. To consider the robustness of our meta-analysis approach,
the 573 tumors from TCGA that had both RNAseq and Agilent microarray
data were assessed for concordance (Supplementary Fig. 1).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
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